No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
JAKK240719C30000
- 0.18
- 0.000.00%
15min DelayClose May 14 15:20 ET
0.00High0.00Low
0.00Open0.18Pre Close0 Volume0 Open Interest30.00Strike Price0.00Turnover3037.41%IV53.98%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier-5DDays to Expiry0.18Extrinsic Value100Contract SizeAmericanOptions Type0.0791Delta0.0261Gamma108.89Leverage Ratio-11.1275Theta0.0000Rho8.61Eff Leverage0.0003Vega
Intraday
- 5D
- Daily
News
Express News | Small Cap Consumer Research Reiterates Buy on Jakks Pacific, Maintains $24 Price Target
JAKKS Pacific Announces Launch of Lifestyle Seasonal Line for Fall
Express News | JAKKS Pacific Shares Are Trading Higher After Small Cap Consumer Research Initiated Coverage With a Buy Rating and Announced a $24 Price Target
Express News | Small Cap Consumer Research Initiates Coverage On Jakks Pacific With Buy Rating, Announces Price Target of $24
Jakks Pacific Analyst Ratings
Owning 46% Shares,institutional Owners Seem Interested in JAKKS Pacific, Inc. (NASDAQ:JAKK),
Comments
Despite JAKKS Pacific's low P/E ratio and predicted future earnings growth, investors remain skeptical due to the company's recent earnings instability and potential risks.
Investors Give JAKKS Pacific, Inc. (NASDAQ:JAKK) Shares A 26% HidingDespite recent share price pullback, the business is doing well enough to support the current price. The transition from loss to profitability justifies a strong share price gain. The share price momentum remains strong, suggesting a closer look at the stock might be worth it.
With shrinking earnings, JAKKS Pacific's low P/E ratio is justified. The potential for earnings improvement isn't seen as enough for a higher P/E ratio, leading to skepticism about significant share price growth.
Gainers:
• $Belite Bio(BLTE.US$ +17.49% (announces that LBS-008 an orally administered tablet has been granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of STGD1)
• $Atkore(ATKR.US$ +12.11% (earnings reports)
• $AST SpaceMobile(ASTS.US$ +9.30% (receives experimental license from FCC for BlueWalker 3 satellite testing)
• $Harmonic(HLIT.US$ +7.56% (earnings reports)
• $The Chemours(CC.US$ +7.2% ...
• $Belite Bio(BLTE.US$ +17.49% (announces that LBS-008 an orally administered tablet has been granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of STGD1)
• $Atkore(ATKR.US$ +12.11% (earnings reports)
• $AST SpaceMobile(ASTS.US$ +9.30% (receives experimental license from FCC for BlueWalker 3 satellite testing)
• $Harmonic(HLIT.US$ +7.56% (earnings reports)
• $The Chemours(CC.US$ +7.2% ...
17
4
Read more